Grading Ductal Carcinoma In Situ (DCIS) of the Breast – What’s Wrong with It?

Gábor Cserni, Anita Sejben

Research output: Contribution to journalReview article

Abstract

Ductal carcinoma in situ of the breast is a non-obligate precursor of invasive breast cancer, and at its lower risk end might not need treatment, a hypothesis tested in several currently running randomized clinical trials. This review describes the heterogeneity of grading ductal carcinoma in situ (DCIS). First it considers differences between low and high grade DCIS, and then it looks at several grading schemes and highlights how different these are, not only in the features considered for defining a given grade but also in their wording of a given variable seen in the grade in question. Rather than being fully comprehensive, the review aims to illustrate the inconsistencies. Reproducibility studies on grading mostly suggestive of moderate agreement on DCIS differentiation are also illustrated. The need for a well structured, more uniform and widely accepted language for grading DCIS is urged to avoid misunderstanding based misclassifications and improper treatment selection.

Original languageEnglish
JournalPathology and Oncology Research
DOIs
Publication statusAccepted/In press - Jan 1 2019

Fingerprint

Carcinoma, Intraductal, Noninfiltrating
Breast
Language
Randomized Controlled Trials
Breast Neoplasms

Keywords

  • Breast cancer
  • Ductal carcinoma in situ
  • Grade

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Oncology
  • Cancer Research

Cite this

Grading Ductal Carcinoma In Situ (DCIS) of the Breast – What’s Wrong with It? / Cserni, Gábor; Sejben, Anita.

In: Pathology and Oncology Research, 01.01.2019.

Research output: Contribution to journalReview article

@article{a1fe57b7150844f0842fc016387cc044,
title = "Grading Ductal Carcinoma In Situ (DCIS) of the Breast – What’s Wrong with It?",
abstract = "Ductal carcinoma in situ of the breast is a non-obligate precursor of invasive breast cancer, and at its lower risk end might not need treatment, a hypothesis tested in several currently running randomized clinical trials. This review describes the heterogeneity of grading ductal carcinoma in situ (DCIS). First it considers differences between low and high grade DCIS, and then it looks at several grading schemes and highlights how different these are, not only in the features considered for defining a given grade but also in their wording of a given variable seen in the grade in question. Rather than being fully comprehensive, the review aims to illustrate the inconsistencies. Reproducibility studies on grading mostly suggestive of moderate agreement on DCIS differentiation are also illustrated. The need for a well structured, more uniform and widely accepted language for grading DCIS is urged to avoid misunderstanding based misclassifications and improper treatment selection.",
keywords = "Breast cancer, Ductal carcinoma in situ, Grade",
author = "G{\'a}bor Cserni and Anita Sejben",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s12253-019-00760-8",
language = "English",
journal = "Pathology and Oncology Research",
issn = "1219-4956",
publisher = "Springer Netherlands",

}

TY - JOUR

T1 - Grading Ductal Carcinoma In Situ (DCIS) of the Breast – What’s Wrong with It?

AU - Cserni, Gábor

AU - Sejben, Anita

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Ductal carcinoma in situ of the breast is a non-obligate precursor of invasive breast cancer, and at its lower risk end might not need treatment, a hypothesis tested in several currently running randomized clinical trials. This review describes the heterogeneity of grading ductal carcinoma in situ (DCIS). First it considers differences between low and high grade DCIS, and then it looks at several grading schemes and highlights how different these are, not only in the features considered for defining a given grade but also in their wording of a given variable seen in the grade in question. Rather than being fully comprehensive, the review aims to illustrate the inconsistencies. Reproducibility studies on grading mostly suggestive of moderate agreement on DCIS differentiation are also illustrated. The need for a well structured, more uniform and widely accepted language for grading DCIS is urged to avoid misunderstanding based misclassifications and improper treatment selection.

AB - Ductal carcinoma in situ of the breast is a non-obligate precursor of invasive breast cancer, and at its lower risk end might not need treatment, a hypothesis tested in several currently running randomized clinical trials. This review describes the heterogeneity of grading ductal carcinoma in situ (DCIS). First it considers differences between low and high grade DCIS, and then it looks at several grading schemes and highlights how different these are, not only in the features considered for defining a given grade but also in their wording of a given variable seen in the grade in question. Rather than being fully comprehensive, the review aims to illustrate the inconsistencies. Reproducibility studies on grading mostly suggestive of moderate agreement on DCIS differentiation are also illustrated. The need for a well structured, more uniform and widely accepted language for grading DCIS is urged to avoid misunderstanding based misclassifications and improper treatment selection.

KW - Breast cancer

KW - Ductal carcinoma in situ

KW - Grade

UR - http://www.scopus.com/inward/record.url?scp=85075926683&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075926683&partnerID=8YFLogxK

U2 - 10.1007/s12253-019-00760-8

DO - 10.1007/s12253-019-00760-8

M3 - Review article

C2 - 31776839

AN - SCOPUS:85075926683

JO - Pathology and Oncology Research

JF - Pathology and Oncology Research

SN - 1219-4956

ER -